Safinamide (mesylate)

Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 μM) over MAO-A (IC50=580 nM) [1]. Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 μM) than at resting (IC50=262 μM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al[2][3].

Product Specifications

CAS Number

[202825-46-5]

Product Name Alternative

FCE 26743 (mesylate) ; EMD 1195686 (mesylate)

UNSPSC

12352005

Hazard Statement

H301, H318, H400

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/safinamide-mesylate.html

Purity

99.07

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : ≥ 20 mg/mL

Smiles

C[C@H](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C(N)=O.CS(=O)(O)=O

Molecular Formula

C18H23FN2O5S

Molecular Weight

398.45

Precautions

H301, H318, H400

References & Citations

[1]Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50 (20), 4909-4916.|[2]C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67 (7 Suppl 2) :S18-23.|[3]Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364 (2) :198-206.